EPMD Announces Abhijeet Lele as New Member of Board of Directors

Business Wire, April 10, 2002

Business Editors

MT. ARLINGTON, N.J.--(BUSINESS WIRE)--April 10, 2002

EP MedSystems, Inc. (NASDAQ: EPMD) today announced the appointment of Abhijeet Lele as a new member of its board of directors.

Abhijeet Lele is a General Partner of EGS Private Healthcare Partnership and EGS Private Healthcare Partnership II, private equity funds focusing on investments in private and public healthcare companies. Before joining EGS, Mr. Lele was a consultant in the healthcare practice of McKinsey & Company and previously held operating positions in the pharmaceutical and biotechnology industries. He holds an MA in molecular biology from Cambridge University and an MBA with distinction from Cornell University. Mr. Lele also serves on the boards of Amarin Corporation (NASDAQ: AMRN), CryoCath Technologies (TSE: CYT), OptiScan Biomedical, Ekos Corporation, InfiMed Therapeutics and Genesis Pharmaceutical.

Reinhard Schmidt, EPMD's President and Chief Operating Officer, commented: "Abhijeet Lele brings to the Board a comprehensive understanding of our Company's products and the electrophysiology specialty. More importantly he brings an understanding of the investment markets in the medical field that will provide unique value to the board. We are excited and look forward to his contribution and strategic guidance with the opportunities before us. This appointment fills the vacancy created by the passing away of Dr. Nigel Roberts last November 2001."

EP MedSystems develops and markets cardiac electrophysiology ("EP") products used to diagnose and treat certain cardiac arrhythmia disorders. The Company's EP product line includes the EP-WorkMate(R) Electrophysiology Workstation, the EP-3(TM) Stimulator, diagnostic electrophysiology catheters, internal cardioversion catheters and related disposable supplies.

This Release contains certain statements of a forward-looking nature relating to future events or the future financial performance of the Company. Such forward-looking statements are only predictions and are subject to risks and uncertainties that could cause actual results or events to differ materially and adversely from the events discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's history of losses, uncertainty of future profitability and future liquidity needs; and risks regarding demand for new and existing products, particularly ALERT(R) System.

The Company cautions investors and others to review the cautionary statements set forth in this Release and in the Company's reports filed with the Securities and Exchange Commission and cautions that other factors may prove to be important in affecting the Company's business and results of operations. Readers are cautioned not to place undue reliance on the interview and other forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this report or to reflect the occurrence of anticipated events.